Senior Analyst; R&D Finance/Accounting
Listed on 2026-09-13
-
Science
Clinical Research
About Summit
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.
Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.
Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.
Summit’s Team Is Inspired To Touch And Help Change Lives Through Summit’s Clinical Studies In The Field Of Oncology. Summit Has Multiple Global Phase 3 Clinical Studies, Including
Non-small Cell Lung Cancer (NSCLC)- HARMONi:
Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3:
Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7:
Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.
- HARMONi-GI3:
Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.
Overview Of RoleReporting to the Senior Manager of Finance, the Senior Analyst (R&D Accounting & Finance) role plays a key part in ensuring accurate financial operations and compliance across the company.
Role And Responsibilities- Support the Sr. Manager, Finance with the monthly close process to ensure timely and accurate financial reporting, with a focus on continuous process improvement and reducing close timelines.
- Prepare and review high visibility CRO entries, Investigator Grant entries and other R&D entries, including those related to Phase 2 and Phase 3 clinical trials.
- Own and review the accounting and financial tracking for clinical trial accruals across multiple Phase 2 and Phase 3 trials, working closely with cross-functional teams to ensure the data is complete, accurate, and audit-compliant.
- Lead site payments process with 3rd party vendor clinical sites by reviewing and validating invoices against Clinical Trial Agreements (CTAs), working with the Clinical Operations and Study Start Up (SSU) teams and resolving any issues quickly and timely.
- Collaborate cross-functionally with other teams such as Clinical Operations and, SSU to support strategic business…
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).